© 2001 by European Society of Cardiology
Copyright © 2000, European Society of Cardiology
Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells
aDepartment of Cardiology, University of Tübingen, Otfried-Müllerstrasse 10, 72076, Tübingen, Germany
bDepartment of Gastroenterology, University of Tübingen, Tübingen, Germany
cDepartment of Cardiosurgery, University of Dresden, Dresden, Germany
dDepartment of Immunology and Cell Biology, University of Münster, Münster, Germany
* Corresponding author. Tel.: +49-7071-298-2711; fax: +49-7071-360-245 bernard_brehm{at}compuserve.com
Objective: Secondary failure due to late restenosis continues to occur in 30–50% of individuals after PTCA. β-Blockers play an important role in the treatment of CAD. The aim of this study was to investigate the effects of the new β-blocker nebivolol on cell proliferation of human coronary smooth muscle cells (haCSMCs) and endothelial cells (haECs) in comparison to traditional β-blockers. Methods: The effect of nebivolol and other β-blockers on proliferation of HaECs and HaCSMCs was analyzed by bromodeoxyuridine incorporation. Apoptosis was measured by determination of hypodiploid DNA in both cell types. Additionally, in HaECs NO formation, endothelin-1 transcription and secretion were determined. Results: Incubation for 1, 2, 4, 7 or 14 days resulted in a concentration- and time-dependent reduction of proliferation up to 80% in HaECs and HaCSMCs. β-Blockers such as propranolol, metoprolol or bisoprolol did not exert this effect. Nebivolol inhibited accelerated haCSMC proliferation even in the presence of growth factors such as TGFβ1 and PDGF-BB. Nebivolol concentration-dependently induced a moderate apoptosis (10–5 mol/l: 23%) and a decrease of haCSMCs in the S-phase by 66%. HaECs showed comparable results. During nebivolol incubation NO formation of HaCEs increased, while endothelin-1 transcription and secretion were suppressed. Conclusion: Whereas classical β-blockers do not affect cell growth, only nebivolol inhibits haCSMC or haEC proliferation and induces a moderate rate of apoptosis. Furthermore, in HaCEs NO formation increases and endothelin-1 secretion decreases suggesting that nebivolol may represent a β-blocker with great promises in CAD therapy.
KEYWORDS Endothelial function; Endothelins; Restenosis; Smooth muscle
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Munzel and T. Gori Nebivolol The Somewhat-Different beta-Adrenergic Receptor Blocker. J. Am. Coll. Cardiol., October 13, 2009; 54(16): 1491 - 1499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Maffei and G. Lembo Nitric oxide mechanisms of nebivolol Therapeutic Advances in Cardiovascular Disease, August 1, 2009; 3(4): 317 - 327. [Abstract] [PDF]
|
|
|
|
|
|
U. Sampat, P. Varadarajan, R. Turk, A. Kamath, S. Khandhar, and R. G. Pai Effect of beta-blocker therapy on survival in patients with severe aortic regurgitation results from a cohort of 756 patients. J. Am. Coll. Cardiol., July 28, 2009; 54(5): 452 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Prisant Nebivolol: Pharmacologic Profile of an Ultraselective, Vasodilatory {beta}1-Blocker J. Clin. Pharmacol., February 1, 2008; 48(2): 225 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Oelze, A. Daiber, R. P. Brandes, M. Hortmann, P. Wenzel, U. Hink, E. Schulz, H. Mollnau, A. von Sandersleben, A. L. Kleschyov, et al. Nebivolol Inhibits Superoxide Formation by NADPH Oxidase and Endothelial Dysfunction in Angiotensin II-Treated Rats Hypertension, October 1, 2006; 48(4): 677 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Wolf, G. Sauter, H.-P. Rodemann, T. Risler, and B. R. Brehm Influence of growth factors on the proliferation of vascular smooth muscle cells isolated from subtotally nephrectomized rats after endothelin or angiotensin II antagonism Nephrol. Dial. Transplant., February 1, 2005; 20(2): 312 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Mollnau, E. Schulz, A. Daiber, S. Baldus, M. Oelze, M. August, M. Wendt, U. Walter, C. Geiger, R. Agrawal, et al. Nebivolol Prevents Vascular NOS III Uncoupling in Experimental Hyperlipidemia and Inhibits NADPH Oxidase Activity in Inflammatory Cells Arterioscler Thromb Vasc Biol, April 1, 2003; 23(4): 615 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R. Brehm, S. C. Wolf, S. Gorner, N. Buck-Muller, and T. Risler Effect of nebivolol on left ventricular function in patients with chronic heart failure: a pilot study Eur J Heart Fail, December 1, 2002; 4(6): 757 - 763. [Abstract] [Full Text] [PDF]
|
|